MY160406A - Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent - Google Patents
Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agentInfo
- Publication number
- MY160406A MY160406A MYPI2010000779A MYPI2010000779A MY160406A MY 160406 A MY160406 A MY 160406A MY PI2010000779 A MYPI2010000779 A MY PI2010000779A MY PI2010000779 A MYPI2010000779 A MY PI2010000779A MY 160406 A MY160406 A MY 160406A
- Authority
- MY
- Malaysia
- Prior art keywords
- pancreatic cancer
- combination therapy
- chemotherapeutic agent
- antigenic peptide
- potentiating
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 title abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95792307P | 2007-08-24 | 2007-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY160406A true MY160406A (en) | 2017-03-15 |
Family
ID=40386893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010000779A MY160406A (en) | 2007-08-24 | 2008-08-19 | Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8703713B2 (OSRAM) |
| EP (1) | EP2195003A4 (OSRAM) |
| JP (1) | JP5417667B2 (OSRAM) |
| KR (1) | KR20100047899A (OSRAM) |
| CN (1) | CN101883577A (OSRAM) |
| AR (1) | AR068020A1 (OSRAM) |
| AU (1) | AU2008292966C1 (OSRAM) |
| BR (1) | BRPI0815726A2 (OSRAM) |
| CA (1) | CA2697501A1 (OSRAM) |
| IL (1) | IL204143A (OSRAM) |
| MX (1) | MX2010002178A (OSRAM) |
| MY (1) | MY160406A (OSRAM) |
| NZ (1) | NZ583578A (OSRAM) |
| RU (1) | RU2472522C2 (OSRAM) |
| SG (1) | SG183770A1 (OSRAM) |
| TW (1) | TWI436775B (OSRAM) |
| UA (1) | UA100702C2 (OSRAM) |
| WO (1) | WO2009028150A1 (OSRAM) |
| ZA (1) | ZA201001580B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| US20080034017A1 (en) * | 2006-08-04 | 2008-02-07 | Dominic Giampaolo | Links to a common item in a data structure |
| TW201109029A (en) | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
| EP2578233B1 (en) * | 2010-05-28 | 2017-04-26 | National Cancer Center | Therapeutic agent for pancreatic cancer |
| DE102013214023B4 (de) * | 2013-07-17 | 2015-02-12 | Siemens Aktiengesellschaft | Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist |
| PL3597742T3 (pl) * | 2014-10-09 | 2022-11-14 | Yamaguchi University | Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR |
| KR102478073B1 (ko) * | 2014-10-14 | 2022-12-16 | 립타이드 바이오사이언스, 인코포레이티드 | 항-염증 특성을 갖는 펩타이드 |
| JP7168228B2 (ja) * | 2017-05-19 | 2022-11-09 | 慶應義塾 | 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 |
| US10413584B1 (en) | 2018-08-29 | 2019-09-17 | Riptide Bioscience, Inc. | Peptides having immunomodulatory properties |
| US10548944B1 (en) | 2018-10-19 | 2020-02-04 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
| CN114959031A (zh) * | 2022-05-20 | 2022-08-30 | 上海交通大学医学院附属瑞金医院 | 胰腺腺癌预后评估的标志物组合及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB213645A (en) | 1922-12-22 | 1924-03-24 | Frank Lincoln Morse | Improvements in and relating to chain and sprocket wheel gearing |
| US3265572A (en) * | 1961-09-20 | 1966-08-09 | S B Penick And Company | Process for preparing tyrociding and product produced thereby |
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| WO1994021679A1 (en) * | 1993-03-25 | 1994-09-29 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
| US6080728A (en) | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| JP3837748B2 (ja) | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Ｖｅｇｆ結合性ポリペプチド |
| WO1999040118A1 (en) | 1998-02-04 | 1999-08-12 | Kyowa Hakko Kogyo Co., Ltd. | Antibodies against human vegf receptor kdr |
| GB9804121D0 (en) | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| WO1999059636A1 (en) | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Vegf activity inhibitors |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| CN103073620B (zh) * | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| ATE507240T1 (de) * | 2004-03-05 | 2011-05-15 | Vegenics Pty Ltd | Materialien und verfahren für wachstumsfaktorbindende konstrukte |
| WO2005117887A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with gemcitabine and an egfr-inhibitor |
| US7691827B2 (en) | 2004-12-17 | 2010-04-06 | Eli Lilly And Company | Amide prodrug of gemcitabine, compositions and use thereof |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| WO2008099908A1 (ja) | 2007-02-16 | 2008-08-21 | Oncotherapy Science, Inc. | 脈絡膜新生血管のワクチン療法 |
-
2008
- 2008-08-13 TW TW097130789A patent/TWI436775B/zh not_active IP Right Cessation
- 2008-08-19 MX MX2010002178A patent/MX2010002178A/es active IP Right Grant
- 2008-08-19 CN CN2008801133893A patent/CN101883577A/zh active Pending
- 2008-08-19 US US12/674,754 patent/US8703713B2/en not_active Expired - Fee Related
- 2008-08-19 RU RU2010111139/15A patent/RU2472522C2/ru not_active IP Right Cessation
- 2008-08-19 MY MYPI2010000779A patent/MY160406A/en unknown
- 2008-08-19 AU AU2008292966A patent/AU2008292966C1/en not_active Ceased
- 2008-08-19 KR KR1020107005967A patent/KR20100047899A/ko not_active Ceased
- 2008-08-19 WO PCT/JP2008/002232 patent/WO2009028150A1/en not_active Ceased
- 2008-08-19 NZ NZ583578A patent/NZ583578A/en not_active IP Right Cessation
- 2008-08-19 EP EP08828542A patent/EP2195003A4/en not_active Withdrawn
- 2008-08-19 BR BRPI0815726A patent/BRPI0815726A2/pt not_active IP Right Cessation
- 2008-08-19 SG SG2012063046A patent/SG183770A1/en unknown
- 2008-08-19 JP JP2010506728A patent/JP5417667B2/ja not_active Expired - Fee Related
- 2008-08-19 CA CA2697501A patent/CA2697501A1/en not_active Abandoned
- 2008-08-19 UA UAA201002881A patent/UA100702C2/ru unknown
- 2008-08-22 AR ARP080103679A patent/AR068020A1/es unknown
-
2010
- 2010-02-24 IL IL204143A patent/IL204143A/en not_active IP Right Cessation
- 2010-03-04 ZA ZA2010/01580A patent/ZA201001580B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008292966A1 (en) | 2009-03-05 |
| MX2010002178A (es) | 2010-03-18 |
| EP2195003A1 (en) | 2010-06-16 |
| RU2010111139A (ru) | 2011-09-27 |
| CA2697501A1 (en) | 2009-03-05 |
| JP5417667B2 (ja) | 2014-02-19 |
| CN101883577A (zh) | 2010-11-10 |
| TWI436775B (zh) | 2014-05-11 |
| JP2010536714A (ja) | 2010-12-02 |
| AU2008292966C1 (en) | 2013-03-14 |
| NZ583578A (en) | 2012-07-27 |
| AU2008292966B2 (en) | 2012-07-19 |
| BRPI0815726A2 (pt) | 2016-01-05 |
| SG183770A1 (en) | 2012-09-27 |
| AR068020A1 (es) | 2009-10-28 |
| ZA201001580B (en) | 2011-02-23 |
| EP2195003A4 (en) | 2011-07-06 |
| TW200914037A (en) | 2009-04-01 |
| US20110082088A1 (en) | 2011-04-07 |
| WO2009028150A1 (en) | 2009-03-05 |
| US8703713B2 (en) | 2014-04-22 |
| KR20100047899A (ko) | 2010-05-10 |
| RU2472522C2 (ru) | 2013-01-20 |
| IL204143A (en) | 2013-04-30 |
| UA100702C2 (ru) | 2013-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY160406A (en) | Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| IL179515A0 (en) | Method of administering and using vegf inhibitors for the treatment of human cancer | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| IL200193A0 (en) | Combination of lbh589 with other therapeutic agents for treating cancer | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| MX2014003180A (es) | Metodos para tratar vhc. | |
| MX2010012860A (es) | Metodos para tratar cancer del sistema nervioso central. | |
| MX2011013577A (es) | Composiciones y metodos para tratar esclerosis lateral amiotrofica. | |
| MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| EP1962839A4 (en) | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER | |
| MX2020001727A (es) | Terapia de combinacion. | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| TN2009000490A1 (en) | Cancer treatment combination therapy comprising vinflunine and trastuzumab | |
| DK1971338T3 (da) | Kombination af ZD6474 og pemetrexed | |
| TN2009000136A1 (en) | Sequential combination therapy | |
| EP2294197A4 (en) | HHIP1 PROTEIN VERSION AND METHOD AND USES THEREOF | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
| EP2124554A4 (en) | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | |
| DK1965801T3 (da) | Kombination af azd2171 og pemetrexed |